-transparent.png){kind=logo}
10 evaluable patients with metastatic hypernephroma received vinblastine (6 mg/m2, i.v., on days 1 and 8), cyclophosphamide (100 mg/m2, p.o., on days 1-14), and 5-fluorouracil (600 mg/m2, i.v., on days 1 and 8), cycled every 29 days. 7 of the patients also received dexamethasone (16 mg/day, p.o), shortly before or during chemotherapy, in an attempt to improve their clinical status. No complete or partial responses were seen. 5 pairs (50%) remained stable (median duration, 4.5 months; medium survival, 6.5 months), and the remaining 5 patients progressed. A subjective response was observed in all stable patients, who also received dexamethasone. The side-effects of VEF chemotherapy were mild: 2/10 patients developed leukopenia (WBC below 3,000), 3/10 patients manifested thrombocytopenia (platelets below 100,000), and 3/10 patients alopecia.
J Halpren, and
G Brufman, and
B Shnider, and
S Biran
December 1983,
Cancer treatment reviews,
J Halpren, and
G Brufman, and
B Shnider, and
S Biran
July 1984,
Journal of surgical oncology,
J Halpren, and
G Brufman, and
B Shnider, and
S Biran
January 1983,
Cancer chemotherapy and pharmacology,
J Halpren, and
G Brufman, and
B Shnider, and
S Biran
October 1978,
Cancer,
J Halpren, and
G Brufman, and
B Shnider, and
S Biran
March 1969,
Cancer,
J Halpren, and
G Brufman, and
B Shnider, and
S Biran
March 1982,
The Journal of urology,
J Halpren, and
G Brufman, and
B Shnider, and
S Biran
October 1983,
Tumori,
J Halpren, and
G Brufman, and
B Shnider, and
S Biran
April 1979,
Cancer,
J Halpren, and
G Brufman, and
B Shnider, and
S Biran
November 1979,
Cancer,
J Halpren, and
G Brufman, and
B Shnider, and
S Biran
July 2001,
Cancer chemotherapy and pharmacology,
